The GeneSight® Precision Medicine Test Drives Significant

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder

SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN ), today announced that a poster featuring the GeneSight ® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado Springs, Colo.

In this subanalysis of a previously published study, patients with generalized anxiety disorder (GAD) experienced significant cost savings when decisions congruent with the GeneSight report were made by healthcare providers.  In the previously published study, congruency with the GeneSight test was shown to deliver significant cost savings for patients with major depressive disorder (MDD).

“We believe that GeneSight has the potential to improve outcomes for patients being treated with psychotropic drugs and eliminate a significant amount of waste in our healthcare system,” said Bryan M. Dechairo, Ph.D., chief medical and science officer, Assurex Health. “We look forward to sharing these data with the medical community and payers.”

Below is a summary of the featured presentation at NEI (#NEI2016). 

Poster Presentation Title: GeneSight Psychotropic Decreases Medication Costs for Patients with Anxiety and Bipolar Disorders in a Large, Prospective Case-Control Project Presenter : Kim Horn. Date: Friday, Nov. 4, 2016: 6:00-7:30 p.m. MT.

This study assessed the economic utility of the GeneSight test for 318 patients with generalized anxiety disorder (GAD) when healthcare providers made decisions congruent with the GeneSight test report. Patients in the GeneSight-guided group of the previously published study were subdivided into two groups. The first group included patients whose healthcare provider made treatment decisions congruent with the GeneSight test report. The second group included patients whose provider made treatment decisions incongruent with the test report. The analysis compared total medication costs between the congruent and incongruent groups for patients based on their diagnosis of GAD.

The results showed that, for GAD patients, the savings for congruent versus incongruent decisions was $6,747 per member per year ($5736 vs $12,483, p<0.004). Importantly, GAD patients experienced greater savings in CNS medications (2-fold), antineoplastic medications (2.5-fold) and gastroenterology medications (2.8-fold). Patients with comorbid GAD and MDD whose medication regimens were congruent with the GeneSight test had the highest cost savings of any group ($10,573). This subanalysis showed significant cost savings for GAD patients when healthcare providers made decisions congruent with the GeneSight test report. Much of the cost savings came from classes of medicines used in primary care.

Anxiety disorders are commonly seen in the primary care setting and are often associated with comorbid medical illnesses, such as heart disease, migraine headaches and back pain for which patients with anxiety often seek help from their primary care provider. The GeneSight test may have enabled healthcare providers to more appropriately treat the underlying anxiety disorder, thereby reducing the number of physical complaints that previously required medication. Additionally, the previously published study showed that patients whose treatment was guided by the GeneSight test experienced increased adherence and reduced polypharmacy, which may have also contributed to cost savings associated with primary care medications.    

About The GeneSight ® Test GeneSight testing helps healthcare providers make better treatment decisions based on a person's genetic makeup. GeneSight testing is based on advanced CPGx ® technology, a patented approach that analyzes variations and combinations of a person's genes along with FDA-approved medications for behavioral health conditions and chronic pain. Peer-reviewed, published studies have proven its clinical benefits and substantial healthcare cost savings. More than 15,000 healthcare professionals have used GeneSight with over 400,000 patients. Learn more at www.GeneSight.com .

About Assurex Health Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc., is an informatics-based, personalized medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. Assurex helps people achieve mental wellness with advanced CPGx ® , a proprietary combinatorial pharmacogenomics technology that provides individualized treatment support for neuropsychiatric conditions. Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of the GeneSight ® test, including its substantial healthcare cost savings benefit. The Company has grown every quarter and has expanded internationally through a partnership with Canada's Centre for Addiction and Mental Health (CAMH). For more on how Assurex Health is helping people gain mental wellness, visit www.AssurexHealth.com .

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting a new study at the Neuroscience Education Institute Annual Meeting being held Nov. 3-6, 2016 in Colorado Springs, Colo.; the accuracy and effectiveness of the GeneSight test in selecting psychotropic drug therapy or saving the healthcare system money; and the Company’s strategic directives under the captions “About GeneSight” and “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 108

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 92

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 207

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 37

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 27

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 159

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading

Top 5 Most Recently Viewed Articles

Trustmark Corporation Schedules Fourth Quarter Earnings Call

Updated Category News Views 204

Trustmark Corporation Plans Q4 Financial Results Announcement Trustmark Corporation (NASDAQGS:TRMK) is set to announce its fourth quarter financial results soon. The announcement will take place through a news release after the market closes. The company plays a vital role in the financial sector with its diverse offerings. Conference Call for Financial Discussion On the...

Continue Reading
VSee Health Experiences Significant Stock Surge After Approval

Updated Category News Views 271

VSee Health Inc. Stock Surges Over 45% Recently, VSee Health Inc. (NASDAQ: VSEE) experienced an impressive jump in its stock price, increasing by 45.28% to reach $1.54 during after-hours trading. This surge marks a notable uptick from its closing price of $1.06 earlier in the day, which represented a remarkable rise of 71.66% according to market data. Impact of Federal...

Continue Reading
Exciting Grand Opening for New Homes in Dacono, CO

Updated Category News Views 193

Exciting Grand Opening for New Homes in Dacono, CO Century Communities, Inc. (NYSE: CCS), a leading national homebuilder celebrated for its innovative approach to online home sales, is thrilled to unveil a Grand Opening event at Sweetgrass in Dacono. This event marks the debut of the community's stunning new model home, bringing an exciting opportunity for potential...

Continue Reading
Shakumoto Housei's Kickstarter: Artisan Neckties Unite People

Updated Category News Views 162

Shakumoto Housei's Journey to Craft Neckties with Heart In today's fast-paced world of fashion, Shakumoto Housei, a cherished small necktie manufacturer from Japan, is embarking on a unique adventure. This family-operated firm aims to connect with the global community through a heartfelt Kickstarter project. Rather than merely producing neckties, the initiative represents...

Continue Reading
Beko's Call for Sustainable Refrigeration in Food Security

Updated Category News Views 108

Refrigeration's Crucial Role in Global Food Security This year's World Food Day theme, 'Right to Foods for a Better Life and a Better Future', emphasizes the importance of worldwide access to food, highlighting the often-overlooked role of refrigeration. A recent report underscores that insufficient and unreliable refrigeration contributes significantly to food spoilage,...

Continue Reading